PHASQ Stock Price, Chart, Stats & News

PhaseBio Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical enterprise, with a primary focus on developing and bringing to market innovative therapeutic solutions for cardiovascular ailments. Its leading drug candidate, bentracimab (PB2452), is a reversal agent designed to counteract the effects of the antiplatelet medication ticagrelor. This compound is currently undergoing Phase III clinical evaluation, targeting individuals suffering from major or life-threatening uncontrolled bleeding, or those who require immediate surgical or invasive interventions.